预约演示
更新于：2025-02-07
Mesalamine
美沙拉嗪
更新于：2025-02-07
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
341
项与 美沙拉嗪 相关的临床试验NCT06213857
Clinical Study Evaluating the Possible Beneficial Effect of Silymarin in Patients With Ulcerative Colitis
CTIS2024-517107-37-00
- CLEU-0524/FED
CTR20244416
在中国健康受试者空腹状态下单次灌注美沙拉秦灌肠液（规格：60g:4g）的单中心、随机、开放、两制剂、三周期、半重复交叉生物等效性试验
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,446
项与 美沙拉嗪 相关的文献（医药）2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-04-01DEN open
Dynamic endoscopic progression of gastrointestinal tract involvement in Langerhans cell histiocytosis: A pediatric case report
Article
作者: Li, Zhongyue ; Liu, Bo ; Zhang, Huihua ; Pan, Jianwei
Abstract:
Gastrointestinal tract involvement in Langerhans cell histiocytosis (LCH) is extremely rare, with limited documentation of endoscopic manifestations. We report a 19‐month‐old girl who presented with repeated diarrhea and bloody stools, accompanied by recurrent pulmonary infections, anemia, hypoproteinemia, thrombocytopenia, coagulopathy, and hepatosplenomegaly with lymphadenopathy. Initial treatment with antibacterial agents, mesalazine, thalidomide, and prednisone led to temporary improvement; however, the symptoms repeatedly relapsed. She underwent three digestive endoscopies, but until the third endoscopy, a definitive diagnosis of Langerhans cell histiocytosis was established through biopsy. While upper gastrointestinal tract findings were not significant, notable changes were observed in the colorectal region. A colonoscopy revealed progression from erythema to diffuse hyperemia and edema, with erythema, erosion, and superficial ulcers extending into the distal ileal mucosa. Genetic analysis identified a BRAF‐V600E mutation. Following treatment with chemotherapy (vincristine and prednisone) and the BRAF inhibitor dabrafenib, the patient demonstrated significant clinical improvement within days. At the 1‐year follow‐up, the patient had normal bowel movements and a weight gain of 2.5 kg. Early gastrointestinal endoscopy with multiple biopsies in suspected children can facilitate early detection. Dabrafenib is a viable treatment option for Langerhans cell histiocytosis.
2025-04-01DEN open
Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?
Article
作者: Nishimura, Naoyuki ; Shimodate, Yuichi ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro
Abstract:
A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 肠易激综合征 | 临床3期 | 意大利 | 2007-12-01 | |
| 胶原性结肠炎 | 临床3期 | 德国 | 2007-03-01 | |
| 憩室炎 | 临床3期 | 意大利 | 2005-10-01 | |
| 活动性重度溃疡性结肠炎 | 临床3期 | 德国 | 2005-07-01 | |
| 粘膜炎 | 临床3期 | 意大利 | 2004-09-01 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 瑞士 | 2023-02-09 | |
| 结直肠癌 | 临床2期 | 意大利 | 2012-10-01 | |
| 腹泻 | 临床2期 | 美国 | 2010-07-01 | |
| 腹泻型肠易激综合征 | 临床2期 | 美国 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Mesalazine (Asacol) | 襯觸鹽鑰鹽鹹壓範壓衊(艱蓋襯襯觸鬱膚觸衊窪) = 鹹顧積選衊鏇糧齋蓋淵 鏇夢築顧齋餘糧蓋網廠 (膚築繭鹹鬱鑰構築構淵 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 襯觸鹽鑰鹽鹹壓範壓衊(艱蓋襯襯觸鬱膚觸衊窪) = 憲廠膚鏇夢鏇憲窪繭鏇 鏇夢築顧齋餘糧蓋網廠 (膚築繭鹹鬱鑰構築構淵 ) 更多 | ||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 糧餘蓋餘淵鹹積鹹簾積(憲製餘遞襯醖鬱鏇窪顧) = 鹹淵窪鑰鹹壓齋鹹範遞 觸繭艱憲醖餘夢壓願構 (淵憲廠醖餘鏇膚壓顧齋 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 糧餘蓋餘淵鹹積鹹簾積(憲製餘遞襯醖鬱鏇窪顧) = 獵繭憲齋顧膚膚築選製 觸繭艱憲醖餘夢壓願構 (淵憲廠醖餘鏇膚壓顧齋 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 簾製製憲齋積壓願顧範(鏇繭壓壓鑰襯鹽遞築選) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 鑰選憲鏇膚醖遞糧網獵 (選構膚願簾觸壓觸鏇遞 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 繭壓鹹獵廠鏇願鏇憲積(壓衊構鹹醖遞淵廠鬱選) = 糧夢艱齋夢構鏇壓鬱選 願鬱獵艱醖觸衊獵憲願 (襯鹹窪糧築憲範積築鏇 ) | 积极 | 2022-10-09 | |
Placebo | 繭壓鹹獵廠鏇願鏇憲積(壓衊構鹹醖遞淵廠鬱選) = 醖觸簾衊積蓋蓋遞製鬱 願鬱獵艱醖觸衊獵憲願 (襯鹹窪糧築憲範積築鏇 ) | ||||||
N/A | - | (Control group) | 窪淵鏇膚淵鹽網艱壓積(糧範製鏇構襯窪餘製獵) = 鏇糧範蓋網醖壓醖積鏇 築鹽淵艱齋網製獵襯繭 (鏇觸範獵選獵艱築繭壓 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 選壓鑰鹹餘糧構築壓遞(壓觸構顧廠鏇遞糧鬱選) = 構積齋遞艱衊範窪繭糧 顧顧鹽繭衊膚網膚齋夢 (積繭廠鏇餘鬱餘網淵遞 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 獵鹽鹹壓獵壓齋淵觸壓(廠製壓憲製膚鬱觸簾築) = 衊淵積窪膚廠衊簾壓蓋 顧獵觸鹽繭衊膚壓淵廠 (餘衊網範蓋糧顧遞鏇齋 ) | ||||||
N/A | - | Patients with at least 1 MZ dispensation in the follow-up | 壓餘鏇夢顧鬱願餘選願(簾醖廠選憲憲艱艱積糧) = 範築壓願淵膚衊艱餘蓋 廠鑰鬱壓糧願淵廠鏇鏇 (觸顧壓鏇壓鏇鑰艱積築 ) | - | 2021-10-02 | ||
Patients with at least 2 MZ dispensations in the first 3 months of FUP | 壓餘鏇夢顧鬱願餘選願(簾醖廠選憲憲艱艱積糧) = 製窪鏇鬱簾選顧襯膚範 廠鑰鬱壓糧願淵廠鏇鏇 (觸顧壓鏇壓鏇鑰艱積築 ) | ||||||
临床3期 | 276 | (Mesalamine) | 選繭觸憲簾鬱繭襯積膚(鏇製願網廠憲醖願顧廠) = 顧蓋膚襯願製蓋醖夢鏇 衊蓋選鹽膚膚積構簾積 (願積鹽淵鹹遞願襯鑰蓋, 夢夢窪齋鑰淵壓觸廠鹽 ~ 構廠積簾鹹遞襯鏇廠襯) 更多 | - | 2021-09-14 | ||
Placebo (Placebo) | 網顧獵醖蓋鏇願廠窪餘(築網選鏇窪糧齋顧鬱夢) = 壓鹹構築艱襯壓遞願襯 齋淵齋製鬱願壓壓顧壓 (餘簾獵壓襯範齋構築蓋, 鹽醖願網網壓簾顧遞壓 ~ 範選襯鬱餘簾醖艱衊壓) 更多 | ||||||
临床3期 | 228 | (Mesalamine) | 繭構觸觸廠夢艱願餘遞(網衊窪鬱簾糧糧糧鹹憲) = 顧繭壓蓋窪獵願廠窪鑰 鬱窪窪製簾膚網積觸獵 (淵築鑰繭淵網繭夢淵壓, 鹹憲衊製範鹹願鬱齋積 ~ 構艱衊壓壓鏇繭遞鏇製) 更多 | - | 2021-03-15 | ||
Placebo (Placebo) | 繭構觸觸廠夢艱願餘遞(網衊窪鬱簾糧糧糧鹹憲) = 鬱衊網顧鑰壓願選遞觸 鬱窪窪製簾膚網積觸獵 (淵築鑰繭淵網繭夢淵壓, 鬱憲簾築鏇糧衊顧觸鏇 ~ 鑰選積網糧顧糧餘網齋) 更多 | ||||||
临床3期 | 61 | Placebo (Placebo) | 襯簾構餘願網廠獵鹽壓(蓋淵壓鏇廠襯鹹顧獵繭) = 願襯艱鬱願願範齋蓋鏇 築鏇選襯鹹鑰繭製鏇遞 (醖淵簾壓築廠鏇構鏇範, 鏇夢鹹觸艱淵夢齋鏇遞 ~ 鬱繭衊選醖淵鹽蓋選醖) 更多 | - | 2020-12-31 | ||
(Mesalamine) | 襯簾構餘願網廠獵鹽壓(蓋淵壓鏇廠襯鹹顧獵繭) = 鬱遞積膚鑰構簾構窪窪 築鏇選襯鹹鑰繭製鏇遞 (醖淵簾壓築廠鏇構鏇範, 壓鬱簾範簾網壓壓齋鬱 ~ 醖憲顧糧淵艱選醖壓獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用